Harmony Biosciences Holdings Inc (HRMY)
34.07
+0.84
(+2.53%)
USD |
NASDAQ |
Nov 22, 16:00
34.07
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Debt to Equity Ratio: 0.3064 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.3064 |
| June 30, 2024 | 0.3461 |
| March 31, 2024 | 0.3686 |
| December 31, 2023 | 0.4145 |
| September 30, 2023 | 0.4096 |
| June 30, 2023 | 0.3947 |
| March 31, 2023 | 0.4324 |
| December 31, 2022 | 0.4757 |
| September 30, 2022 | 0.5575 |
| June 30, 2022 | 0.778 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.8946 |
| December 31, 2021 | 1.029 |
| September 30, 2021 | 1.264 |
| June 30, 2021 | 1.546 |
| March 31, 2021 | 1.807 |
| December 31, 2020 | 1.999 |
| September 30, 2020 | 2.040 |
| June 30, 2020 | -3.901 |
| March 31, 2020 | -3.868 |
| December 31, 2019 | -8.455 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-8.455
Minimum
Dec 2019
2.040
Maximum
Sep 2020
-0.0581
Average
0.4541
Median
Debt to Equity Ratio Benchmarks
| Regeneron Pharmaceuticals Inc | 0.0677 |
| Incyte Corp | 0.00 |
| EyePoint Pharmaceuticals Inc | 0.00 |
| Cassava Sciences Inc | -- |
| Capricor Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 928.14M |
| Total Liabilities (Quarterly) | 331.33M |
| Shareholders Equity (Quarterly) | 596.80M |
| Current Ratio | 3.239 |
| Net Debt Paydown Yield | 0.08% |